Overview

Study of Imatinib-Combined Chemotherapy for BCR-ABL-Positive Acute Lymphoblastic Leukemia (ALL)

Status:
Completed
Trial end date:
2008-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the clinical efficacy and safety of imatinib-combined chemotherapy on newly diagnosed BCR-ABL-positive ALL.
Phase:
Phase 2
Details
Lead Sponsor:
Japan Adult Leukemia Study Group
Treatments:
Cyclophosphamide
Cytarabine
Daunorubicin
Dexamethasone
Imatinib Mesylate
Methotrexate
Prednisolone
Vincristine